Biotech innovator Liquidia, specializing in pulmonary therapies, reported a notable insider sale amid continued growth in its ...

Wearable device data may help detect and track idiopathic pulmonary arterial hypertension, a rare lung disease, a study ...

Cautionary Language Concerning Forward-Looking Statements ...

WILMINGTON, DE — Inhibikase Therapeutics Inc. (Nasdaq: IKT) has enrolled the first patient in its Phase 3 clinical trial ...

Scottish Medicines Consortium approves new NHS Scotland drugs for lung cancer, leukaemia, cervical cancer, pulmonary ...

Positive airway pressure therapy is linked with reduced pulmonary arterial pressures in patients with severe obstructive sleep apnea or obesity hypoventilation syndrome.

Hypertension is the leading modifiable risk factor for atrial fibrillation (AF) and is estimated to be present in >70% of AF patients. This Frontiers Review was prepared by 29 expert members of the AF ...

Abstract: Pulmonary hypertension (PH) is a fatal pulmonary vascular disease. The standard diagnosis of PH heavily relies on an invasive technique, i.e., right heart catheterization, which leads to a ...

Pulmonary hypertension is a condition where specialist input is essential, yet the day-to-day management of many patients takes place in local hospitals, usually in general respiratory clinics, far ...

Pulmonary hypertension (PH) is a progressive disease marked by pulmonary arterial remodeling and right ventricular dysfunction. The molecular mechanisms driving this remodeling, particularly ECM ...